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Abstract: Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional
BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor
predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One
hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying
BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or
variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter
methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples
and results were compared with those in controls. All the 108 analyzed cases showed methylation
levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev)
at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively
(p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and
3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations;
the analysis of constitutional methylation at promoters of these genes does not seem to substantially
improve the definition of cancer risks in patients. These data support the idea that epimutations
represent a very rare event in high-risk BC/OC populations.
Keywords: germline epigenetic defects; BRCA1; RAD51C; promoter methylation; breast carcinoma;
ovarian carcinoma
1. Introduction
Epigenetic alterations, i.e., epimutations, are an emerging mechanism that plays a pivotal
role in carcinogenesis. Several studies demonstrated that defects in epigenetic markers, such as
modifications of CpG methylation at gene promoters, result in transcriptional silencing of active genes
or activation of silent genes, causing effects similar to those of gene mutations. Particularly, DNA
methylation at CpG sites located in promoter regions of tumor-suppressor genes is a well-described
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event that could be present: (i) only in tumor cells, i.e., somatic epimutations, (ii) at the germline
level, with evidence of inheritance, i.e., linked to cis-acting mutations [1,2] or, finally, (iii) in multiple
tissues of different embryonic origin with no evidence of inheritance and often in a mosaic state, i.e.,
constitutional epimutations.
Regarding breast and ovarian cancer (BC and OC), mutations in BRCA1, along with BRCA2 and
few other genes, are responsible for only a fraction of familial cases. Moreover, somatic epimutations in
these genes are nowadays largely studied to understand not only their involvement in tumorigenesis
but also their effects on therapy response, such as at cisplatin and PARPi [3,4]. The study of germline
and constitutional epimutations in BC and OC related genes is a relatively novel research field. Recently,
Evans and colleagues reported the first case of germline BRCA1 methylation in two families affected by
Hereditary Breast and Ovarian Cancer Syndrome. The BRCA1 promoter resulted hemi-methylation in
all cells and it was linked to a cis-acting 5’UTR promoter variant [5]. Constitutional BRCA1 methylation
was analyzed by different groups with multiple technical approaches and it has been demonstrated to
be associated with an increased risk of developing BC and/or OC [6–11]. Indeed, constitutional BRCA1
methylation has been related to early onset of the disease and to basal-like phenotypes in case of BC,
especially the triple negative (TN) subtype, and high-grade serous histotypes in the case of OC. Along
with BRCA1, other BC/OC-related genes have been investigated. Among these, RAD51C was found
constitutively hypermethylated in sporadic BC, as showed by Hansmann and colleagues [10], who
identified hypermethylation at both BRCA1 and RAD51C promoters in 1.4% and 0.5% of high-risk
cancer patients, respectively. The authors noted that epimutations were present in 5.5%, (2/37) sporadic
early-onset BC patients, 0.9% (4/460) familial BC patients, and in 10% (4/39) of OC patients. Moreover,
epimutations were confined to one of the two parental alleles always at the mosaic level in tissues of
different embryonic origins. This indicated that they occurred in a single cell relatively early during
the embryonic development. This model was further supported by recent studies demonstrating that
the majority of constitutional BRCA1 methylation events arose early during development and seemed
to remain quite stable during life and potentially were inherited from mother to daughter [12,13].
This novel hypothesis of inheritance is controversial and needs further studies to be completely
elucidated [13].
Apart from the etiopathogenesis of this phenomenon, its prevalence is still debated. Depending
on the studies, it ranges from less than 1% to 15%. This lack of homogeneity might be due to different
composition of the patients’ cohorts as well as to the different nature of the technical approaches applied
to profile methylation, which were not always quantitative. Defining the prevalence of constitutional
epimutations in BC and OC might improve screening strategies for identifying women at increased
risk who may benefit from tailored preventive options.
Our group recently reported constitutional BRCA1 methylation in one out of 154 selected isolated
early-onset BC patients, exploiting an accurate quantitative approach and establishing strict analysis
parameters [11].
Based on the previous findings, we tried to clarify the prevalence of constitutional epimutations
in BC and OC predisposition by analyzing the methylation status of BRCA1 and RAD51C promoters in
108 women affected by BC and/or OC, with high a priori risk of harboring pathogenetic variants at
BRCA1 and who tested negative for BRCA sequence variants.
2. Results
BRCA1 and RAD51 Methylation Levels
As shown in Figure 1a, none of the 108 analyzed cases exceeded the fixed minimum
hypermethylation threshold defined in controls (threshold values were 13.6% and 12.1% for BRCA1
and RAD51C, respectively). In detail, mean methylation levels (± stdev) of the BRCA1 promoter region
were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05, t-test); mean
methylation levels (± stdev) of the RAD51C promoter region were 4.3% (± 0.9%) and 3.7% (± 0.9%) in
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controls and patients, respectively (p > 0.05, t-test). These overall data are consistent with the absence,
in the investigated population, of germline or constitutive mosaic epigenetic alterations, resulting in
BRCA1 or RAD51C promoter hypermethylation.
We also investigated possible differences in methylation levels among clinical subgroups, without
finding significant differences. In particular, patients affected with BC-only showed methylation levels
at BRCA1 and RAD51C comparable with those affected with OC-only (p > 0.05, t-test). In detail,
BRCA1 mean methylation was 4.3% (± 0.93%) and 3.9% (± 0.97%) in patients with BC- or OC-only,
respectively. RAD51C mean methylation was 3.7% (± 0.91%) and 3.5% (± 0.56%) in patients with BC-
or OC-only, respectively (Figure 1b). No differences were noted among different histological subtypes
of both BC and OC, albeit the number of cases in each subgroup might be too small to highlight
slight discrepancies.
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3. Discussion
This study evaluated the presence of DNA hypermethylation at promoter regions of BRCA1
and RAD51C genes in peripheral blood lymphocytes from women affected by BC and/or OC who
tested negative at the BRCA analysis, although they w re at high risk to harbor pathogenic variants.
The rationale of the study was based on previous findings on the possible influence of germline
hypermethylation of cancer predisposing gene promoters [1,2] in a few conditions including breast
cancer [14].
The BRCA1 and RAD51C genes were selected as potential candidate genes based on previous
studies and on the phenotype of patients included in the study. While BRCA1 is the most recognized
predisposing gene for BC and OC, RAD51C was first identified as a putative cancer-predisposing gene
in BC/OC families in 2010 [15]. Subsequently, it was confirmed to be associated with an increased
Cancers 2020, 12, 910 4 of 8
risk of OC and, only recently, of BC, in particular of the TN type [16,17]. Moreover, to date somatic
epimutations in both BC [5,10,18,19] and OC [10,19,20] have been identified only at these two genes.
In our study, none of the patients exhibited increased methylation levels at BRCA1 and RAD51C
promoters, with respect to the control population. No statistical differences were detected among
specific subgroups, in particular patients affected with BC only and those affected with OC only.
Although this result might be burdened by the limited size of our cohort, our approach,
based on highly selective inclusion criteria, should have maximized the chances of identifying
potentially causative epimutations. Therefore, we hypothesize that epimutations, either germline
or constitutional, represent a very rare event in women with BC and/or OC who tested negative at
the BRCA analysis, although they were at high risk to harbor pathogenic variants. This finding also
supports previous reports [21,22], highlighting the absence of germline epimutations at BRCA1 or other
BC/OC-predisposing genes in similar cohorts. Moreover, this result is in line with our previous study
on isolated early-onset BC patients, which demonstrated the extremely low frequency of constitutional
epiphenomena in a different subgroup of patients considered to be at increased risk to carry cancer
predisposing alterations [11].
In the attempt to clarify the importance of epimutations, instead of genetic variants, in cancer
predisposition genes, a number of technical limitations should be taken into account: (i) blood might not
be the ideal tissue, since the hypermethylation could be present in a mosaic condition and blood may
be not involved in the alteration; (ii) the sensitivity of the methylation detection may not completely
exclude the presence of constitutional mosaic epimutations. In our analyses the lower threshold of
hypermethylation was relatively high (i.e., +0.5 above the one-sided 95% bootstrap confidence interval)
and archival tumor samples were not available for this study, therefore we were able to investigate
germline epimutations though we could not completely rule out the presence of mosaic epimutations.
Nevertheless, a mosaic hypermethylation would not fit in with the family history of most of our
patients, who reported multiple BC/OC affected family members.
Additional factors, not assessed in the present study, including age or chemotherapy treatment,
might affect methylation levels in blood. Notwithstanding, we previously investigated some of these
factors on a cohort of isolated early onset BC patients and found that blood methylation at these loci
was stable regardless of age at blood withdrawal or previous chemotherapy [11].
4. Materials and Methods
4.1. Study Subjects
A total of 108 patients were selected among individuals who underwent genetic counseling and
testing at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT). All patients enrolled in
the study were affected by either BC, OC, or both and were considered at very high risk of carrying a
BRCA1 pathogenic variants based on personal and/or family history. Patients who fulfilled one of the
four criteria reported in Table 1 were included in the study.
Table 1. Study cohort composition following the reported inclusion criteria. BC, breast cancer; OC,
ovarian cancer; TNBC, triple negative breast cancer.
Inclusion Criteria n. Patients
(1) BC < 50 years + high mutation probability 73
(2) OC any age + high mutation probability 19
(3) TNBC < 55 years + high mutation probability 10
(4) BC < 50 years/TNBC any age + OC any age 6
All the BC cases were either invasive or ductal carcinomas in situ (DCIS). All the OC included
in the analysis were not of the mucinous type or low grade. A “high mutation probability” was
defined as ≥30% according to the BRCAPRO model (CaGene software version 5.1; PMID 9443863,
http://www4.utsouthwestern.edu/breasthealth/cagene/) or either ≥30% for BRCA1/BRCA2 or ≥60% for
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BRCA1/BRCA2 plus a hypothetical third gene, which would account for all the other BC-associated
genes in BRCA-negative families, according to the case-only-study, COS software [23]. All the selected
patients were negative for pathogenic variants (including large deletions/duplications) or variants of
uncertain significance (VUS) in BRCA1 and BRCA2.
All patients underwent the methylation analysis on peripheral blood leukocytes (PBLs).
Eighty-nine patients developed BC, with a median age at onset of 34 years (range 24–71 years).
Among these women, 11 developed ipsilateral BC (median age 40, range 36–61), 23 contralateral BC
(median age 45, range 33–65), and 6 OC (median age 54.5, range 40–78). Among the 19 patients who
developed OC, but not BC, the median age at onset was 61 (range 32–76). The age at blood withdrawal
ranged from 27 to 78 years (median 46). The main histopathological features of BC and OC cases
included in the study are reported in Tables 2 and 3, respectively.
Table 2. Main features of breast cancer cases in the study cohort. BC, breast cancer; OC, ovarian cancer;
TN, triple negative; ER, estrogen receptor, PgR, progesterone receptor; SD, standard deviation; N.A.,
data not available; * not in-situ lobular carcinoma.
Breast Cancer Features BC-Only Patients BC+OC Patients
No. 83 6
1st BC age (years)
Mean ± SD 35 ± 6 46 ± 13
Median 33 43
Range 24–51 36–71
1st BC Invasive
Yes 77 (93%) 5 (83%)
No (CDIS) 2 (2%) 1 (17%)
N.A.* 4 (5%) 0
1st BC Histotype
Ductal 66 (79%) 5 (83%)
Lobular 4 (5%) 0
Mixed 3 (4%) 1 (17%)
Other 7 (8%) 0
N.A. 3 (4%) 0
1st BC Grade
I 7 (8%) 0
II 18 (22%) 1 (17%)
III 30 (36%) 1 (17%)
N.A. 28 (34%) 4 (67%)
1st BC pT
Is 1 (1%) 1 (17%)
1 35 (42%) 1 (17%)
2 15 (18%) 3
3 2 (2,5%) 0
4 2 (2,5%) 0
N.A. 28 (34%) 1 (17%)
1st BC ER
Pos 39 (47%) 1 (17%)
Neg 26 (31%) 1 (17%)
N.A. 18 (22%) 4 (67%)
1st BC PgR
Pos 38 (46%) 0
Neg 27 (32%) 2 (33%)
N.A. 18 (22%) 4 (67%)
1st BC HER2
Pos 9 (11%) 0
Neg 29 (35%) 2 (33%)
N.A. 45 (54%) 4 (67%)
1st BC TN Yes 10 (12%) 1 (17%)
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Table 3. Main features of ovarian cancer cases in the study cohort. BC, breast cancer; OC, ovarian
cancer; SD, standard deviation; N.A., data not available.
Ovarian Cancer Features OC-Only Patients BC + OC Patients
No. 19 6
OC Age (Years)
Mean ± SD 58 ± 12 57 ± 12
Median 61 54.5
Range 32–76 40–78
OC Histotype
Serous 12 (63%) 3 (50%)
Endometrioid 3 (16%) 3 (50%)
Undifferentiated 3 (16%) 0
Clear cell 1 (5%) 0
OC Grade
II 5 (26%) 4 (67%)
III 14 (74%) 2 (33%)
OC Stage
1 1 (5%) 2 (33%)
2 1 (5%) 0
3 5 (26%) 2 (33%)
4 2 (11%) 0
N.A. 10 (53%) 2 (33%)
The analysis was also carried out in a control population of 60 women, selected among healthy
blood donors at the Immunohematology and Transfusion Medicine Service of our Institution. The age
at blood withdrawal in controls ranged from 21 to 59 years (median 41).
All participants provided a signed informed consent for the use of their biological samples and
data for research purposes. The investigations were conducted in accordance with the Declaration of
Helsinki and the study was approved by the Ethics Committee of INT (approval code INT 171/15).
4.2. DNA Extraction and Bisulfite Conversion
Genomic DNA was purified from PBLs using the MagCore Super instrument and the MagCore
Genomic DNA Whole Blood Kit (Diatech Lab Line, JEsi, Italy, CE-IVD). Bisulfite conversion was
conducted on 500 ng of DNA using the EZ Direct DNA Methylation Kit (Zymo Research, Irvine, CA,
USA), following the manufacturer’s instructions.
4.3. Epityper Mass Spectrometry
Methylation analyses were performed according to the procedure implemented by our group
in a previous study [11]. MassARRAY® EpiTYPER platform, with MassCleave settings, was used to
determine methylation levels of BRCA1 and RAD51C promoter regions. The BRCA1 and RAD51C PCR
primers were the same as the previous study and amplified about 400 bp of the promoters [11]. As
previously described [11], two human commercial control DNA samples were used as methylated and
non-methylated control samples, Human HCT116 DKO Methylated DNA and Human HCT116 DKO
Non-Methylated DNA (Zymo research corporation).
4.4. Statistical Pipeline
Methylation data in the patients’ cohort were analyzed and classified as hypo- or hyper-methylated
by comparison with methylation levels obtained in a control population, composed of 60 healthy
women, as reported in Azzollini et al., 2019. Briefly, the mean methylation level of the selected CpGs
within each promoter (9 CpG sites for BRCA1 and 11 for RAD51C) was calculated. A thousand
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bootstrap samples were generated based on the distribution of the mean methylation levels in
controls and the one-sided 95% percentile bootstrap confidence interval (bCI) of the controls’ mean
was derived [11]. Cases were considered hypermethylated when their mean promoter methylation
exceeded the one-sided 95% bCI by 0.05.
5. Conclusions
Considering all the above, this study confirmed that, in our cohorts, both germline and
constitutional epimutations represent a very rare event in BC and OC carcinogenesis. Based on
these observations, although additional data are needed to better characterize the prevalence of this
phenomenon, the analysis of constitutional methylation at promoters of known cancer-predisposing
genes does not seem to significantly improve the definition of cancer risk.
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